{
  "meta": {
    "title": "Acute_Leukemias",
    "url": "https://brainandscalpel.vercel.app/acute-leukemias-121c8b06.html",
    "scrapedAt": "2025-11-29T18:31:57.157Z"
  },
  "questions": [
    {
      "id": 15335,
      "choices": [
        {
          "id": 61300,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated total leukocyte count </span></span></span></p>"
        },
        {
          "id": 61301,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leucocyte alkaline phosphatase </span></span></span></p>"
        },
        {
          "id": 61302,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erythrocyte sedimentation rate </span></span></span></p>"
        },
        {
          "id": 61303,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of immature cells</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The difference between leukemia and leukemoid reaction is done by:</span></span></span></p>",
      "unique_key": "Q8514067",
      "question_audio": null,
      "question_video": null,
      "map_id": 32006,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Leucocyte alkaline phosphatase </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leukocyte alkaline phosphatase (LAP) </strong>is a marker that can help d<strong>istinguish between chronic myeloid leukemia (CML) and a leukemoid reaction</strong>. In CML,<strong> LAP is typically low, </strong>while in a <strong>leukemoid reaction, it is normal or elevated. </strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Elevated total leukocyte count:</strong>&nbsp;<strong>Both leukemia and leukemoid reaction </strong>can result in an <strong>elevated total leukocyte count. </strong>However, the specific characteristics of the white blood cells, along with other parameters, help differentiate between the two.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Erythrocyte sedimentation rate (ESR):&nbsp;</strong>is a<strong> non-specific marker of inflammation </strong>and is not commonly used to differentiate between leukemia and leukemoid reaction. </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Presence of immature cells: </strong>The <em>presence</em> of<strong> immature or blast cells </strong>is <strong><em>not helpful</em> </strong>for differentiating between <strong>leukemia from a leukemoid reaction. </strong>The <strong><em>percentage of immature cells</em></strong> is a crucial factor in distinguishing leukemia from a leukemoid reaction.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leukocyte alkaline phosphatase (LAP) </strong>score helps differentiate between <strong>chronic myeloid leukemia (CML), where it is typically low</strong>, and a<strong> leukemoid reaction, where it is normal or elevated.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 584)</span></span></em></strong></span></span></span></em></strong></p>",
      "correct_choice_id": 61301,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15318,
      "choices": [
        {
          "id": 61232,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blasts of acute myeloid leukemia are typically Su&shy;dan black negative </span></span></span></p>"
        },
        {
          "id": 61233,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blasts of acute lymphoblastic leukemia are typically myeloperoxidase positive </span></span></span></p>"
        },
        {
          "id": 61234,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low leucocyte alkaline phosphatase score is charac&shy;teristically seen in blastic phase of chronic myeloid leukemia </span></span></p>"
        },
        {
          "id": 61235,
          "text": "<p><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tartarate resistant acid phosphatase positivity is typically seen in hairy cell leukemia</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements pertaining to leukemia is correct?</span></span></span></p>",
      "unique_key": "Q2631088",
      "question_audio": null,
      "question_video": null,
      "map_id": 32010,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Tartarate resistant acid phosphatase positivity is typically seen in hairy cell leukemia </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tartarate resistant acid phosphatase (TRAP) </strong>positivity is a hallmark feature of<strong> hairy cell leukemia (HCL). </strong>This staining helps to distinguish<strong> HCL from other lymphoproliferative disorders </strong>and is positive in the<strong> majority of HCL cases</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Blasts </strong>in<strong> acute myeloid leukemia (AML) </strong>are often<strong> Sudan black positive</strong>. This histochemical stain is used to detect the presence of <strong>myeloid granules in blasts</strong>, which are typically <strong>abundant in AML cells</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Blasts of acute lymphoblastic leukemia (ALL) </strong>are generally <strong>myeloperoxidase (MPO) negative</strong>. MPO is an enzyme found predominantly in<strong> myeloid cells </strong>and is used as a marker to<strong> distinguish AML (where blasts are typically MPO positive) from ALL</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>low leukocyte alkaline phosphatase (LAP) </strong>score is seen in the chronic phase of<strong> chronic myeloid leukemia (CML), </strong>reflecting the abundance of <strong>immature leukocytes. </strong>However, the <strong>LAP score </strong>often<strong> increases </strong>when <strong>CML progresses to the blast crisis phase</strong>, due to the presence of a <strong>higher </strong>proportion of <strong>mature leukocytes.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tartarate resistant acid phosphatase (TRAP) positivity </strong>is typically seen in <strong>hairy cell leukemia (HCL), </strong>which is useful for its <strong>diagnosis and differentiation</strong> from other <strong>hematologic disorders.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 604) </span></span></em></strong></p>",
      "correct_choice_id": 61235,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15338,
      "choices": [
        {
          "id": 61312,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute lymphoblastic leukemia </span></span></span></p>"
        },
        {
          "id": 61313,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute myelogenous leukemia </span></span></span></p>"
        },
        {
          "id": 61314,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic lymphocytic leukemia </span></span></span></p>"
        },
        {
          "id": 61315,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic myelogenous leukemia </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of the Philadelphia chromosome is associated with a worse prognosis in patients with which of the following diseases?</span></span></span></p>",
      "unique_key": "Q9651393",
      "question_audio": null,
      "question_video": null,
      "map_id": 32007,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Acute lymphoblastic leukemia </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Acute Lymphoblastic Leukemia, ALL):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In ALL, the presence of the <strong>Philadelphia chromosome</strong>, which involves the <strong>translocation t(9;22) resulting in the BCR-ABL1 fusion gene</strong>, is associated with a<strong> more aggressive disease </strong>course and a <strong>poorer prognosis. </strong>This is because the<strong> BCR-ABL1 fusion protein has increased tyrosine kinase activity</strong>, which drives the <strong>leukemogenesis. </strong>Patients with <strong>Philadelphia chromosome-positive ALL </strong>often require<strong> more </strong>intensive treatment, such as <strong>tyrosine kinase inhibitors (TKIs) </strong>in addition to<strong> chemotherapy</strong>, and may be considered for <strong>stem cell transplantation.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: (Acute Myelogenous Leukemia, AML):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The <strong>Philadelphia chromosome</strong> is <strong>not </strong>commonly associated with <strong>AML</strong>. AML has other chromosomal abnormalities that are<strong> more predictive of prognosis</strong>, such as the presence of mutations in genes like<strong> FLT3, NPM1, or alterations like t(15;17) in acute promyelocytic leukemia (APL).</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: (Chronic Lymphocytic Leukemia, CLL):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> CLL is typically <strong>not</strong> associated with the<strong> Philadelphia chromosome.</strong> CLL has its own prognostic markers, such as<strong> deletions in chromosome 13q, 11q, and trisomy 12</strong>, or the mutation status of <strong>IGHV (immunoglobulin heavy chain variable region genes).</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: (Chronic Myelogenous Leukemia, CML):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The<strong> Philadelphia chromosome </strong>is the <strong>hallmark of CML</strong> and is present in the vast majority of cases. The<strong> presence of this chromosome </strong>is part of the diagnostic criteria for <strong>CML </strong>and is <strong>not </strong>considered a<strong> worse prognostic factor </strong>within this disease context. The treatment for CML includes<strong> TKIs</strong>, which target the<strong> BCR-ABL1 protein </strong>resulting from the<strong> Philadelphia chromosome translocation.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of the<strong> Philadelphia chromosome</strong>, a <strong>translocation from the long arm of chromosome 22 to chromosome 9 [t(9;22)], </strong>is associated with a<strong> favorable prognosis </strong>in <strong>chronic myelogenous leukemia but</strong> it associated with an <strong>unfavorable outcome in Acute lymphoblastic leukemia</strong>. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 601) </span></span></em></strong></p>",
      "correct_choice_id": 61312,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15328,
      "choices": [
        {
          "id": 61272,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M1</span></span></p>"
        },
        {
          "id": 61273,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M3</span></span></p>"
        },
        {
          "id": 61274,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M2</span></span></p>"
        },
        {
          "id": 61275,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M4</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">AML with gum infiltration and hepatosplenomegaly is most likely associated with which of the following subtypes of AML?</span></span></span></p>",
      "unique_key": "Q2333307",
      "question_audio": null,
      "question_video": null,
      "map_id": 32002,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) M4<em> </em></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(M4 - Acute Myelomonocytic Leukemia):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> M4 </strong>subtype includes features of <strong>both myeloblastic and monocytic lineage. </strong>The monocytic component has a predilection for <strong>tissue infiltration, </strong>such as <strong>gum hypertrophy and skin involvement (leukemia cutis), </strong>making this <strong>subtype more</strong> likely to present with<strong> gum infiltration and hepatosplenomegaly.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: (M1 - Acute Myeloblastic Leukemia without maturation):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> M1 subtype is characterized by a <strong>proliferation of myeloblasts without </strong>significant<strong> differentiation</strong>. While<strong> organomegaly can occur</strong>, M1 is<strong> not </strong>typically associated with <strong>gum infiltration.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: (M3 - Acute Promyelocytic Leukemia):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> M3 subtype </strong>is unique due to its association with the<strong> t(15;17) translocation </strong>and the <strong>PML-RARA fusion gene</strong>. It can present with <strong>disseminated intravascular coagulation (DIC),</strong> but <strong>gum infiltration</strong> is<strong> less </strong>characteristic of <strong>M3</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: (M2 - Acute Myeloblastic Leukemia with maturation):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>M2 </strong>subtype shows some <strong>degree of myeloid maturation</strong>. It can occasionally involve<strong> extramedullary sites</strong>, but<strong> gum infiltration and hepatosplenomegaly </strong>are <strong>more typical of AML with monocytic differentiation</strong>, such as <strong>M4 and M5</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Acute Myelomonocytic Leukemia (M4) </strong>is commonly associated with extramedullary manifestations such as <strong>gum infiltration and hepatosplenomegaly </strong>due to the<strong> infiltrative nature of the monocytic component </strong>of the leukemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 618) </span></span></em></strong></p>",
      "correct_choice_id": 61275,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15319,
      "choices": [
        {
          "id": 61236,
          "text": "<p><span style=\"font-size:12pt;\">TLC 4000-10000</span></p>"
        },
        {
          "id": 61237,
          "text": "<p><span style=\"font-size:12pt;\">Age between 1-10 years</span></p>"
        },
        {
          "id": 61238,
          "text": "<p><span style=\"font-size:12pt;\">Presence of testicular involvement at presentation</span></p>"
        },
        {
          "id": 61239,
          "text": "<p><span style=\"font-size:12pt;\">Presence of blasts in peripheral smear</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Which of the following is having poor prognosis in ALL?&nbsp;</span></p>",
      "unique_key": "Q6229189",
      "question_audio": null,
      "question_video": null,
      "map_id": 32011,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Presence of testicular involvement at presenta­tion</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>(Presence of testicular involvement at presentation):</strong> Testicular involvement at presentation is considered an <strong>adverse prognostic factor in ALL</strong>. It suggests<strong> extramedullary disease</strong>, which can be associated with a<strong> higher risk of relapse </strong>and may require <strong>more intensive treatment, </strong>including <strong>radiotherapy.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A: (TLC 4000-10000):</strong> Total leukocyte count (TLC) at presentation is an important<strong> prognostic factor in ALL</strong>. <strong>Normal or moderately elevated TLCs </strong>are generally associated with a<strong> better prognosis</strong>. A <strong>very high TLC</strong>, particularly above <strong>100,000, </strong>is typically considered a <strong>poor prognostic indicator in ALL</strong>, particularly in<strong> T-cell ALL</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B: (Age between 1-10 years):</strong> age less than 1 year or more than 10 years has&nbsp;poor&nbsp;prognosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D: (Presence of blasts in peripheral smear):</strong> The presence of <strong>blasts </strong>in the peripheral blood smear is characteristic of ALL but on its own is<strong> not necessarily a poor prognostic indicator</strong>. The percentage and the<strong> total number of blasts </strong>can provide <strong>more specific prognostic information</strong>, with a <strong>higher burden </strong>sometimes indicating<strong> more aggressive disease.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>presence of testicular </strong>involvement at presentation in <strong>Acute Lymphoblastic Leukemia (ALL) </strong>is associated with a<strong> poorer prognosis </strong>due to the risk of<strong> extramedullary relapse </strong>and the need for <strong>more aggressive treatment</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Poor Prognostic Factors in ALL:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Age &lt; 1 or &gt; 10 years</span></li><li><span style=\"font-size:12.0pt;\">TLC &gt; 50,000/µL</span></li><li><span style=\"font-size:12.0pt;\">CNS or testicular involvement</span></li><li><span style=\"font-size:12.0pt;\">Philadelphia chromosome (BCR-ABL)</span></li><li><span style=\"font-size:12.0pt;\">Poor response to induction therapy</span></li><li><span style=\"font-size:12.0pt;\">Hypodiploidy</span></li></ul>",
      "correct_choice_id": 61238,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15300,
      "choices": [
        {
          "id": 61160,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genotyping/karyotyping</span></span></span></p>"
        },
        {
          "id": 61161,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immunophenotyping </span></span></p>"
        },
        {
          "id": 61162,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bone marrow </span></span></span></p>"
        },
        {
          "id": 61163,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripheral smear study </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adult patient presents with generalized lymphadenop&shy;athy and blood film shows 70% immature looking lym&shy;phocytes. What should be the next best investigation?</span></span></span></p>",
      "unique_key": "Q4148394",
      "question_audio": null,
      "question_video": null,
      "map_id": 32004,
      "difficulty_level": "difficult",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Immunophenotyping </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Immunophenotyping </strong>is the process of analyzing the types of <strong>surface markers expressed on cells</strong>, which is crucial for diagnosing <strong>different types of leukemia and lymphomas</strong>. This would be the most appropriate<strong> next step for identifying the specific type of leukemia</strong>, as it allows for the classification of the lymphocytes<strong> based on their surface markers.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Genotyping/Karyotyping </strong>is used to detect <strong>chromosomal abnormalities and gene mutations, </strong>which can provide information on <strong>prognosis and guide treatment</strong>, but it is<strong> not typically the first step following a blood film analysis </strong>showing<strong> immature lymphocytes</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Bone Marrow Aspiration/Biopsy </strong>is used to examine the<strong> morphology of marrow cells and architecture</strong>, which can confirm a diagnosis <strong>suggested by immunophenotyping</strong>, but it&#39;s usually <strong>not the first follow-up test </strong>when a<strong> specific leukemia subtype </strong>is suspected from a <strong>blood smear</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Peripheral Smear Study </strong>is an <strong>initial investigation </strong>that has already been <strong>performed, showing immature lymphocytes</strong>. This prompts further <strong>investigation </strong>with more specific tests like<strong> immunophenotyping, rather than repeating the same analysis</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of<strong> immature lymphocytes </strong>in a patient with <strong>generalized lymphadenopathy </strong>strongly suggests a need for <strong>immunophenotyping </strong>to identify the specific type of <strong>leukemia</strong>. It may be <strong>chronic lymphocytic leukemia </strong>which can be picked up by certain<strong> surface markers </strong>like <strong>CD19, CD20, CD23, and CD5.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 597) </span></em></strong></span></span></p>",
      "correct_choice_id": 61161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15315,
      "choices": [
        {
          "id": 61220,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ALL </span></span></span></p>"
        },
        {
          "id": 61221,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">AML </span></span></span></p>"
        },
        {
          "id": 61222,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mixed phenotypic leukaemia </span></span></span></p>"
        },
        {
          "id": 61223,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Undifferentiated leukaemia </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 6-year-old child presents with pallor that required two blood transfusions previously. He has now developed fever and petechial haemorrhages. His hemoglobin is 9 g/dL, platelet count is 20,000/mm<strong><sup>3</sup> </strong>and TLC is 60,000/mm<strong><sup>3</sup></strong>. Flow cytometry reveals the cells to be CD10+ve, MPO+ ve, CD 19 + ve, CD 33 &ndash; ve, CD 117 + ve, and CD3 &ndash; ve. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q8154056",
      "question_audio": null,
      "question_video": null,
      "map_id": 32008,
      "difficulty_level": "difficult",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Mixed phenotypic leukaemia</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><strong> </strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mixed Phenotypic Leukemia (MPL):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> MPL, also known as <strong>mixed lineage or biphenotypic leukemia, </strong>is characterized by the presence of both <strong>lymphoid and myeloid </strong>markers on <strong>leukemic cells</strong>. This type of leukemia is rare and can be<strong> challenging to treat</strong>. The diagnosis is made by identifying <strong>specific combinations </strong>of markers from<strong> different lineages on the same cells, </strong>as demonstrated by the<strong> flow cytometry </strong>results provided in the<strong> vignette (CD10, CD19, MPO, CD117 positive and CD33, CD3 negative).</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Lymphoblastic Leukemia (ALL):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ALL is a malignancy characterized by the<strong> overproduction of immature lymphoid cells</strong>, known as <strong>lymphoblasts, </strong>in the bone marrow. It is the most common type of cancer in<strong> children </strong>and is characterized by the presence of<strong> B or T lymphoid markers</strong>, but not typically myeloid markers. The flow cytometry results in the<strong> vignette showing CD10 and CD19 positivity </strong>suggest a<strong> lymphoid origin</strong>, which would be consistent with <strong>ALL. </strong>However, the presence of <strong>MPO</strong>, which is a <strong>myeloid marker, makes pure ALL less likely</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute Myeloid Leukemia (AML):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AML is a malignancy of <strong>myeloid lineage cells </strong>and is associated with the presence of myeloid markers such as<strong> CD13, CD33, </strong>and <strong>myeloperoxidase (MPO).</strong> It usually presents with signs of <strong>bone marrow failure like anemia, infection, and bleeding due to dysfunctional hematopoiesis</strong>. <strong>CD117 </strong>can also be present in<strong> AML</strong>. In the given case, the presence of<strong> MPO and CD117 supports myeloid involvement, </strong>but the additional presence of<strong> B-cell markers (CD10, CD19) would be atypical for AML</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Undifferentiated Leukemia:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Undifferentiated leukemia </strong>is a term used when l<strong>eukemic cells </strong>do not express <strong>lineage-specific markers </strong>that allow classification as either<strong> myeloid or lymphoid</strong>. These cells may express <strong>non-lineage specific markers like CD34, HLA-DR, and TdT, </strong>but <strong>lack </strong>definitive markers for<strong> B-cell, T-cell, or myeloid cell lines. </strong>In the vignette, the presence of lineage-specific markers does not support the diagnosis of undifferentiated leukemia.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective: </span></u></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>B </strong>lymphoid markers: <strong>CD10, CD19 and CD79 </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>T </strong>lineage markers:<strong> CD2, CD3 and CD7 </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Myeloid markers</strong>;<strong> CD13, CD33, CD117 and myeloperoxidase (MPO). </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Non lineage </strong>specific markers of hematopoietic progenitor cells:<strong> CD34, HLA-DR and TdT </strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/picture6.jpg\" style=\"height:242px; width:700px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Wintrobes 12<sup>th</sup> /1814-8, Dacie and Lewis hematol&shy;ogy 10<sup>th</sup> /344-6)</span></em></strong></span></span></p>",
      "correct_choice_id": 61222,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15317,
      "choices": [
        {
          "id": 61228,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">M3</span></span></span></p>"
        },
        {
          "id": 61229,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M4</span></span></p>"
        },
        {
          "id": 61230,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M5</span></span></p>"
        },
        {
          "id": 61231,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">M6</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-specific esterase is positive in all the categories of AML except:</span></span></span></p>",
      "unique_key": "Q8276309",
      "question_audio": null,
      "question_video": null,
      "map_id": 32009,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) M6 </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(M6 - Acute Erythroid Leukemia):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> M6, also known as <strong>acute erythroid leukemia or erythroleukemia, </strong>is a rare form of AML characterized by a proliferation of <strong>erythroid precursors. </strong>It <strong>does not </strong>typically show<strong> NSE positivity </strong>because this enzyme marker is <strong>not </strong>associated with the <strong>erythroid lineage.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: (M3 - Acute Promyelocytic Leukemia, APL):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> M3 or APL is characterized by a<strong> specific chromosomal translocation t(15;17), </strong>which leads to the production of the <strong>PML-RARA fusion protein. </strong>The morphological hallmark of<strong> APL </strong>is the presence of <strong>promyelocytes with heavy granulation and Auer rods</strong>. Nonspecific esterase staining may be positive in a minority of APL cases, but this is not the main diagnostic marker. <strong>APL </strong>is particularly associated with a risk of <strong>disseminated intravascular coagulation</strong> (DIC) and is treated uniquely with <strong>all-trans retinoic acid (ATRA) and arsenic trioxide</strong>, which target the<strong> PML-RARA fusion protein.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: (M4 - Acute Myelomonocytic Leukemia):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> M4 or acute myelomonocytic leukemia is characterized by the proliferation of <strong>both myeloid and monocyte cells</strong>.<strong> Nonspecific esterase </strong>staining is<strong> positive</strong> because of the <strong>monocytic component,</strong> distinguishing it from other forms of<strong> AML</strong>. These cells often show<strong> dual esterase </strong>staining when stained with <strong>both specific and nonspecific esterase, </strong>reflecting their <strong>mixed lineage.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: (M5 - Acute Monocytic Leukemia):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> M5 or acute monocytic leukemia is characterized by an <strong>excess of monocytes </strong>in the <strong>bone marrow and blood</strong>. <strong>Nonspecific esterase </strong>staining is <strong>strongly positive </strong>in these cells, which reflects the presence of the <strong>monocytic component</strong>. M5 can be further<strong> subdivided into M5a and M5b</strong>, based on the<strong> maturity of the monocytes.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Non-specific esterase (NSE) </strong>staining is characteristic of<strong> M4 and M5 subtypes of AML </strong>due to their <strong>monocytic components </strong>and is not a feature of the <strong>M6 class</strong>, which is marked by a <strong>proliferation of erythroid precursors.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/618) </span></span></em></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em><span style=\"font-size:12.0pt\"><span style=\"color:black\"> </span></span></em></strong></span></span></p>",
      "correct_choice_id": 61231,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15331,
      "choices": [
        {
          "id": 61284,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acid phosphatase</span></span></span></p>"
        },
        {
          "id": 61285,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-specific esterase </span></span></span></p>"
        },
        {
          "id": 61286,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myeloperoxidase </span></span></p>"
        },
        {
          "id": 61287,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Toluidine blue </span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old man was referred with a 2 week history of fever weakness and bleeding gum. Peripheral smear showed pancytopenia. The bone marrow examination revealed 26% blasts frequency exhibiting Auer rods and mature myeloid cells. An occasional neutrophil with pseudo Pelger-Huet anomaly was also detected. Which of the following cytochemical stains is most likely to be positive? </span></span></span></p>",
      "unique_key": "Q3445553",
      "question_audio": null,
      "question_video": null,
      "map_id": 32003,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Myeloperoxidase<em> </em></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Patient </strong>here gives a <strong>short history (acute onset) </strong>of development of <strong>pancytopenia (fever; weakness and gum bleeding suggest leucopenia; anemia and thrombocytopenia respectively).</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Myeloperoxidase):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Myeloperoxidase (MPO) is an enzyme found in <strong>myeloid cells</strong>, particularly <strong>myeloblasts, </strong>and its presence is a <strong>hallmark of AML</strong>. AML blasts, especially those with <strong>Auer rods</strong>, which are<strong> highly </strong>suggestive of<strong> AML</strong>, will usually be <strong>MPO positive.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: (Acid Phosphatase):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Acid phosphatase staining is primarily used to identify cells of the <strong>T-lymphoid lineage </strong>and is a key diagnostic marker in <strong>T-cell acute lymphoblastic leukemia (ALL). </strong>It would<strong> not </strong>typically be <strong>positive in myeloid cells or AML</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: (Non-Specific Esterase):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Non-specific esterase staining is characteristic of <strong>monocytes and their malignant counterparts in acute monocytic leukemia (AML M5 subtype). </strong>It&#39;s not a specific marker for myeloblasts, which are the predominant cells in most AML subtypes.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: (Toluidine Blue):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Toluidine blue staining is used to highlight <strong>mast cells </strong>and is not typically used in the diagnosis of<strong> AML or other types of leukemia</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with <strong>acute onset of pancytopenia and 26% blasts </strong>exhibiting<strong> Auer rods in the bone marrow</strong>, <strong>myeloperoxidase (MPO) </strong>staining is most likely to be<strong> positive</strong>, supporting a diagnosis of<strong> Acute Myeloid Leukemia (AML).</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 621) </span></span></em></strong> </span></span></span></span></p>",
      "correct_choice_id": 61286,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15333,
      "choices": [
        {
          "id": 61292,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">t (15;17) </span></span></span></span></p>"
        },
        {
          "id": 61293,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">t (9;22) </span></span></span></span></p>"
        },
        {
          "id": 61294,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">t (17;21) </span></span></span></span></p>"
        },
        {
          "id": 61295,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">t (8: 21) </span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chromosomal translocation characteristic in acute promyelocytic leukemia is: </span></span></span></p>",
      "unique_key": "Q4794327",
      "question_audio": null,
      "question_video": null,
      "map_id": 32005,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. t (15: 17) </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">t (15;17):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>chromosomal translocation </strong>that is characteristic of<strong> Acute Promyelocytic Leukemia (APL). </strong>It involves the fusion of the <strong>PML (promyelocytic leukemia) </strong>gene on<strong> chromosome 15 with the RARA (retinoic acid receptor alpha) </strong>gene on<strong> chromosome 17. </strong>The resulting <strong>PML-RARA fusion gene </strong>is<strong> oncogenic</strong>, leading to the development of<strong> APL</strong>.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: t (9;22):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This translocation is characteristic of<strong> Chronic Myelogenous Leukemia (CML) </strong>and is known as the<strong> Philadelphia chromosome. </strong>It involves the fusion of the <strong>BCR (breakpoint cluster region) </strong>gene on <strong>chromosome 22 with the ABL1 (Abelson murine</strong> <strong>leukemia viral oncogene homolog 1) </strong>gene on <strong>chromosome 9, </strong>resulting in the <strong>BCR-ABL1 fusion gene</strong>. This fusion gene produces a constitutively active<strong> tyrosine kinase</strong>, contributing to the pathogenesis of<strong> CML.</strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: t (17;21):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This translocation is <strong>not a well-known </strong>chromosomal abnormality in<strong> leukemia. </strong>It doesn&#39;t correspond to a recognized leukemia subtype.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: t (8;21):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This translocation is characteristic of <strong>Acute Myeloid Leukemia (AML) </strong>with maturation<strong> (AML-M2 subtype). </strong>It involves the fusion of the <strong>AML1 (also known as RUNX1) gene on chromosome 21 with the ETO (Eight-Twenty-One) gene on chromosome 8</strong>, resulting in the <strong>AML1-ETO fusion gene</strong>. This translocation is associated with a subtype of AML and is used in its classification.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> chromosomal translocation </strong>characteristic of <strong>Acute Promyelocytic Leukemia is t(15;17), </strong>resulting in the <strong>PML-RARA fusion gene</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><em><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><em><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 613) </span></span></em></strong> </span></span></span></em></strong></p>",
      "correct_choice_id": 61292,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}